IL-23 Blockade in Anti-TNF Refractory IBD: From Mechanisms to Clinical Reality.

"Conflict of Interest R.A. has served as a speaker, or consultant, or received research grants from AbbVie, Amgen, Arena Pharmaceuticals, Biogen, Boehringer Ingelheim, Bristol-Myers Squibb, Cellgene, Celltrion Healthcare, DrFalk Pharma, Ferring, Fresenius Kabi, Galapagos, Gilead, GlaxoSmithKline plc, InDex Pharmaceuticals, Janssen-Cilag, Kliniksa Pharmaceuticals, Lilly, MSD Sharp & Dohme, Novartis, Pandion Therapeutics, Pfizer, Roche Pharma, Samsung Bioepsis, Stelic Institute, Sterna Biologicals, Takeda Pharma, Tillotts Pharma AG, Viatris. M.F.N. reports research grants and/or personal fees from Abbvie, MSD, Takeda, Boehringer, Roche, Pfizer, Janssen, Pentax and PPD."

"Funding Funding by the German Research Council (DFG) SFB1181 [project no. C02] and SFB/TRR241 [project no. C02, IBDome]. The German Research Council [DFG] funds the Heisenberg Professorship of R.A. This paper was published as part of a supplement financially supported by AbbVie."